
National Jun 3, 2022
Skin rash more common in women after Moderna shot, Japan study finds
by Tomoko Otake
Swelling, pain and/or itchiness of the arm that received the vaccine was also more common among people in their 30s through 60s.
Skin rash more common in women after Moderna shot, Japan study finds
Swelling, pain and/or itchiness of the arm that received the vaccine was also more common among people in their 30s through 60s.
We need better COVID-19 booster shots, not more of the same
There are 100 new Covid vaccines in development. One of them could offer better protection against omicron.
With sumo flag sponsorship deal, COVID vaccine-maker Moderna reveals Japan ambition
The U.S. firm is seeking to build on its newfound renown in COVID-19 vaccines and wrestle market share from compatriot Pfizer Inc.
Fourth COVID shot provides little benefit against omicron, study shows
The study took place when spread of the omicron variant was rife in Israel, and it found that the fourth dose didn't confer much added protection against infection.
Japan's booster rollout is relying on Pfizer and Moderna. How do the shots compare?
Despite an apparent preference among some in the general public for Pfizer, experts have emphasized that getting a booster jab as soon as one is eligible, no matter which type, is key.
The news comes a day after rival vaccine developer Pfizer Inc. launched a similar trial.
The decades of discoveries before the ‘miraculous’ sprint to a vaccine
The breakthroughs behind the vaccines unfolded over decades, little by little, as scientists across the world pursued research in disparate areas.
Singapore breaks down COVID-19 deaths by vaccine, with Moderna seeing lowest rate
While there were some caveats, the findings will likely add to concerns around the efficacy of Sinovac’s and Sinopharm Group’s shots, which have been widely used in the developing world.
The ins and outs of Japan's COVID-19 booster shot rollout
Japan recommends people receive a different shot for their third doses to the one they received in the initial rollout, but what's the rationale behind that strategy?
Moderna says its booster dose appears protective against omicron
The data, which has not yet been peer reviewed, tested blood from people who had received the vaccine against a pseudovirus engineered to resemble the omicron variant.
Kishida asks Pfizer to expedite supply of further vaccines to Japan
Japan is looking to move up the third round of shots by revising the planned eight-month interval between second jabs and boosters.
The deal underscores efforts by governments around the world to build up local production and prepare for future pandemic threats.